A carregar...
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence. Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients does not recur and might thus be overtreated...
Na minha lista:
| Main Authors: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3008599/ https://ncbi.nlm.nih.gov/pubmed/21081926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605916 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|